Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.

In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.

[4][5] In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.

[6] Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.